TORONTO, Sept. 30 /CNW/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced changes to its Board of Directors.
Dr. Ed Miller, the Dean and Chief Executive Officer of Johns Hopkins
University School of Medicine, notified Bradmer that since the Company has
entered into discussions with Johns Hopkins as a site for its Phase III
Neuradiab(TM) trial, he is required to remove himself from the Board to avoid
any potential conflict of interest. Dr. Miller will be replaced on the Board
by Dr. Donald Kufe, Professor of Medicine, Harvard Medical School and
Director, Experimental Therapeutics Program, Dana-Farber/Harvard Cancer
Center.
